Insurance data reveals dramatic regional differences in the use of GLP-1 medications like Ozempic and Mounjaro, with states having higher obesity rates prescribing these drugs at triple the rate compared to other regions. New agreements from President Donald Trump are expected to lower prices on popular weight-loss drugs, potentially boosting their usage. Experts predict expanded applications beyond diabetes and obesity, including cardiovascular and cancer treatments. Dr. Brett Osborn, a Florida neurologist, highlights the growing role of GLP-1s in managing various health conditions. The Trust for America’s Health report indicates that 19 states have adult obesity rates of at least 35%, with no state now having an obesity rate below 25%. The data underscores the growing role of these medications in addressing public health challenges, though structural barriers to healthy living remain a key concern.